United States: Ropes & Gray Advises Pacira Pharmaceuticals In Reaching Landmark Settlement Agreement With FDA

A cross-disciplinary team of Ropes & Gray attorneys advised Pacira Pharmaceuticals on its December 14 settlement agreement with FDA. On behalf of Pacira, Ropes & Gray had filed suit against FDA in September 2015 in the U.S District Court for the Southern District of New York, alleging that the agency had violated Pacira's First and Fifth Amendment rights, as well as the Administrative Procedure Act, in issuing a Warning Letter in 2014 that had accused Pacira of engaging in off-label marketing of EXPAREL®, the company's flagship drug. In its complaint and motion for a preliminary injunction, Pacira contended that the marketing claims cited by FDA in the Warning Letter were "on-label," rather than "off-label" as alleged by the agency; additionally, Pacira argued that even if its speech were deemed off-label, the speech was truthful and non-misleading and thus deserving of First Amendment protection. The pharmaceutical industry has been following the litigation closely as an indication how this approach of combining administrative and constitutional claims might fare in the wake of recent favorable First Amendment decisions relating to pharmaceutical manufacturers' marketing.

By teaming its veteran appellate and government enforcement litigators up with its expert FDA regulatory attorneys, Ropes & Gray helped Pacira win a resounding victory in the case. As described below, under the terms of the settlement agreement, FDA took the unprecedented step of withdrawing its Warning Letter, confirming that Pacira's promotional claims for EXPAREL were in fact on-label. Additionally, to clarify ambiguities that gave rise to the Warning Letter, FDA agreed to approve significant revisions to the EXPAREL label.

Background on Litigation

On September 8, 2015, Pacira filed a lawsuit against FDA seeking to gain clarity about the scope of EXPAREL's approval and to exercise its rights to communicate truthful and non-misleading information. The lawsuit followed the company's previously unsuccessful attempts to engage FDA in a dialogue regarding allegations made by FDA in the 2014 Warning Letter. Although FDA had approved EXPAREL in 2011 for "administration into the surgical site to produce postsurgical analgesia," the Warning Letter alleged that Pacira could not promote EXPAREL for use in surgeries other than bunionectomy and hemorrhoidectomy, the two sites studied in Pacira's pivotal clinical trials. The Warning Letter also asserted that Pacira could not make claims about EXPAREL's duration of effectiveness over 72 hours, even though that was the primary endpoint of one of the drug's pivotal trials.

Three prominent experts submitted declarations supporting Pacira's lawsuit. Dr. Larry Goldkind, a former high-ranking FDA official, described how the Warning Letter was inconsistent with both FDA's 2011 approval of EXPAREL and the agency's long-standing policy and practices relating to approval of analgesic drugs more generally. Dr. Lee-Jen Wei, a tenured professor of biostatistics at Harvard, explained that one of EXPAREL's pivotal trials demonstrated a significant treatment effect for EXPAREL compared to placebo for up to 72 hours. And Dr. Alex Cahana, a specialist in pain medication, described the substantial public health benefits of communicating information about non-opioid pain drugs such as EXPAREL.

Highlights of Settlement Agreement

The settlement confirms, as Pacira had maintained throughout, that EXPAREL is, and has at all times been, broadly approved to provide postsurgical analgesia and that Pacira did not violate the law by marketing EXPAREL for use in surgical sites beyond the two sites studied in its pivotal clinical trials. The key features of the settlement are as follows:

First, in an unprecedented move, FDA rescinded the Warning Letter and issued a new letter to Pacira explaining the reasons for the withdrawal (the " rescission letter"). The rescission letter, signed by Janet Woodcock, Director of the Center for Drug Evaluation and Research, acknowledged that the EXPAREL label as initially approved "created ambiguity with respect to the scope of the approved indication" and that upon further review, FDA concluded that the Warning Letter was based on a misreading of the EXPAREL label. The rescission letter also conceded that the plain language of the Indications and Usage section in the EXPAREL label, as well as the pivotal clinical trials submitted to FDA, made clear that EXPAREL is approved for postsurgical analgesia in surgical sites generally, and that the approval is not limited to bunionectomy and hemorrhoidectomy procedures.

Second, FDA approved a significant revision to the EXPAREL label to address certain ambiguities in the EXPAREL label that gave rise to the Warning Letter. In particular, the new label makes clear that EXPAREL is indicated for use in surgical sites generally, not just the two sites studied in EXPAREL's pivotal trials. Additionally, the revised Dosing and Administration section provides general guidance on selecting the proper EXPAREL dose for the planned surgical site and indicates that the dosing information from the two pivotal trials provides examples from which practitioners may extrapolate for administration in other surgical sites. The label also deletes language characterizing the duration of effect of EXPAREL in one of the pivotal studies and replaces it with a more balanced explanation of the data regarding effectiveness.

Doug Hallward-Driemeier of Ropes & Gray LLP, attorney for Pacira, stated, "We have long argued that the FDA Warning Letter to Pacira was issued in error because it was based on FDA's misinterpretation of the approved indication for EXPAREL and the clinical evidence supporting the drug's approval. We are pleased that the agency took the extraordinary steps of withdrawing the Warning Letter and revising the EXPAREL label, both of which fully vindicate our client and its lawful and appropriate promotional practices."

The Ropes & Gray cross-practice team representing Pacira included appellate & Supreme Court partner Doug Hallward-Driemeier; FDA regulatory partner Joy Liu; government enforcement partner Joan McPhee; FDA regulatory counsel Kellie Combs; business & securities litigation counsel Justin Florence; business & securities litigation associate Julian Helisek; and litigation associates Emerson Siegle and John Dey.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions